HiddoLambers Heerspink Netherlands

Hiddo Lambers Heerspink is affiliated with the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, the Netherlands. He received his PhD degree from the medical faculty of the University Medical Center Groningen in 2008. He then worked as a post-doctoral fellow at The George Institute in Sydney, Australia where he was trained in clinical trial design and conduct, and investigated the effects of blood pressure lowering regimens on renal and cardiovascular outcomes in patients with CKD. Based on this work, he was awarded a young investigator grant and subsequently in 2015 a consolidator investigator grant from the Dutch organisation of scientific research. rSince 2010, Doctor Lambers Heerspink has held a position as a Clinical Pharmacologist at the University Medical Center Groningen. He is currently Professor Clinical Trials and Personalized Medicine. His main research interests include optimising treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease. His particular clinical research interest is to identify determinants of individual treatment responses and ways to optimize drug response in individual patients. To achieve these goals he is involved in various international clinical trials and uses biomarkers and imaging techniques to unravel pathways and determinants of therapy response.
Institution

Day 2 - Monday April 15, 2024

Time Session
4:30 p.m.
5:30 p.m.
SK05
DebbieGipson Chairperson debbie.gipson@nih.govUnited StatesNational Institutes of Health/NIDDK
JonathanBarratt Chairperson United KingdomUniversity of Leicester, Leicester, UK
  • Patients Subphenotyping: The Example of Diabetic Kidney Disease
    John CijiangHe Speaker cijiang.he@mssm.eduUnited StatesIcahn School of Medicine at Mount Sinai
  • Power of AI to Develop Data-driven Early Detection, Diagnosis, and Management of Kidney Disease
    LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan
  • Targeted Approaches in Clinical Trial Design
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall D

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10:30 a.m.
IK04
CarlosSchreck Chairperson carlos.schreck@gmail.comArgentinaHospital Italiano de Buenos Aires- Nephrology
KellyHaughton Chairperson kidneydoctorpanama@gmail.comPanamaSLANH, Panama
  • Why Are Fewer Than I% Of Hypertensive Patients Ever Screened For Primary Aldosteronism?
    John Funder Speaker John.Funder@hudson.org.auAustraliaThe Hudson Institute of Medical Research Clayton 3168 Victoria Australia; Monash University, Clayton 3600 Victoria Australia
  • Aldosterone and Disease
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUnited StatesUniversity of Pennsylvania
  • New Trials Using Aldosterone Synthese Blockade
    MichelAzizi Speaker michel.azizi@aphp.frFranceUniversité Paris Cité, Hypertension department, Hô
  • Targeting MR for Heart and Kidney Protection
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall E